| Identification | Back Directory | [Name]
GAMMA-SECRETASE INHIBITOR | [CAS]
133407-83-7 | [Synonyms]
Z-LLNLE-CHO
Z-LEU-LEU-NLE-CHO
Z-LEU-LEU-NLE-ALDEHYDE
γ-Secretase Inhibitor I
CBZ-Leu-Leu-Nle-Aldehyde
GAMMA-SECRETASE INHIBITOR
GAMMA-SECRETASE INHIBITOR I
Cbz-leucinyl-leucinyl-norleucinal
L-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formylpentyl]-
benzyl N-[4-methyl-1-[[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate | [Molecular Formula]
C26H41N3O5 | [MDL Number]
MFCD02179375 | [MOL File]
133407-83-7.mol | [Molecular Weight]
475.62 |
| Hazard Information | Back Directory | [Uses]
gamma-Secretase Inhibitor I is a γ-secretase inhibitor. | [Biological Activity]
Cell permeable: yes''Primary Target
γ-secretase''Product does not compete with ATP.''Reversible: no | [in vivo]
Z-LLNle-CHO (5 mg/kg; s.c.; single daily for 12 days) inhibits engraftment of B-lymphoblasts in precursor-B ALL xenograft model[2]. | Animal Model: | Female SCID/NOD mice (6-8-week-old; precursor-B ALL xenograft model)[2]. | | Dosage: | 5 mg/kg | | Administration: | Subcutaneous injection; single daily for 12 days | | Result: | Delayed or prevented engraftment of B-lymphoblasts in 50% of the animals comprising the experimental group. |
|
|
|